Reports Q3 revenue $287.268M, consensus $247.7M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “Six quarters into Rezdiffra’s launch, we continue to execute on all fronts. Most gratifying is the impact we’re having, with more than 29,500 patients on therapy and more than 10,000 healthcare providers prescribing Rezdiffra. With quarterly sales now annualizing above $1 billion, Rezdiffra is quickly becoming one of the most successful specialty launches in the industry and we’re still early, with greater than 90 percent of our target population yet to be treated. As we look ahead to 2026, Rezdiffra is poised for growth and continued broad, first-line access for patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms
- Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA
- MDGL Upcoming Earnings Report: What to Expect?
- Sagimet Biosciences initiated with a Buy at Clear Street